Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can directly determine the outcome of gene transfer. Here, we show that prior exposure to AAV drives distinct capsid immunity profiles in healthy subjects. In peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive donors, recombinant AAV triggered TNF-α secretion in memory CD8+ T cells, B cell differentiation into antibody-secreting cells, and anti-capsid antibody production. Conversely, PBMCs isolated from AAV-seronegative individuals appeared to carry a population of NK cells reactive to AAV. Further, we demonstrated that the AAV capsid activates IL-1β and IL-6 cytokine secretion in monocyte-related dendritic cells (moDCs). IL-1β and IL-6 blockade inhibited the anti-capsid humoral response in vitro and in vivo. These results provide insights into immune responses to AAV in humans, define a possible role for moDCs and NK cells in capsid immunity, and open new avenues for the modulation of vector immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recent work has highlighted the role of innate immune system in response to AAV therapeutics (42–46)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [43]
In the citing paper
“Adaptive anti-capsid humoral [27] and cytotoxic [28, 29] immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [27]
In the citing paper
“Studies suggest that following secondary AAV exposure, capsid-specific memory T cells produce cytokines and acquire a cytotoxic phenotype [27, 106–108].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [27]
In the citing paper
“moDCs have been previously identified as the main cells secreting IL-6 and IL-1β in response to AAV in human blood (43)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [43]
In the citing paper
“Although Kuranda et al. showed induction of pro-inflammatory cytokines IL-6 and IL-1b upon exposure of human PBMCs with empty AAV capsid, they did not directly implicate TLR2 for this pro-inflammatory milieu.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 1×
“These cells showed increased TNF-α and granzyme B secretion and signs of recent activation/exhaustion, indicated by PD-1 upregulation (41).”
BackgroundOf Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 2×
“Additionally, in mice, the TLR2 expression pattern and regulation are different (70) and, unlike in humans (13), anti-AAV antibody formation in mice is TLR2 independent (21).”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 9×
“Our study supports this hypothesis, as it shows that CD8+ T cells restimulated with the VP1372–380 epitope (22) secrete cytotoxic granules (CD107a) in the presence of target cells, without concomitant IFN-γ secretion.”
BackgroundMethodInfluentialSelf-citationRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“org Volume 128 Number 12 December 2018 Introduction With several successful adeno-associated virus (AAV) vector– based gene therapy clinical trials (1–4) and the recent approval by the FDA of a gene therapy for congenital blindness (5), the promise of a definitive cure for numerous genetic diseases is becoming a reali…”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“We used the AAV8 serotype, which is highly homologous to AAV2 (49) but has a greater capacity to transduce murine hepatocytes (50).”
MethodLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationHuman NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211 · cited 1×
“Indeed, these cells are prominent innate immune effectors known to rapidly respond to infection without prior sensitization and are activated by target cells rather than by the sole presence of cytokines (75).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“The ICS assays performed ex vivo or after 1 cycle on AAV2, as it naturally infects humans and is therefore the most seroprevalent of all AAV serotypes (44).”
BackgroundSelf-citation
Research works printed but not linked: 1
- 10.1016/j.cellimm.2017.07.12 · doi:10.1016/j.cellimm.2017.07.12
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“A recent study investigating antibody formation against AAV in healthy humans found that production of IL-1b and IL-6 by circulating monocyte-derived DCs (moDCs) upon pulsing with AAV particles or AAV capsid-derived peptides activated B cells (Figure 3).(72) Blockage of either cytokine suppressed antibody formation ag…”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“By conventional and CyTOF mass cytometry,(48) we observed that exposure of human PBMCs to AAV capsid epitopes induced the activation of CD8 T cells with an effector memory phenotype, which secreted predominantly TNF-a, but also cytolytic granules containing granzyme B and CD107a.(42) Alternatively, in seronegative pat…”
BackgroundInfluentialSelf-citationHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Additionally, the monitoring of cytokines other than IFN-γ may be helpful in more effectively monitor T cell activation following rAAV vector administration (52) (Figure 3).”
BackgroundMethodInfluentialSelf-citationEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
Self-citationKonkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Kruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Adaptive anti-capsid humoral [27] and cytotoxic [28, 29] immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
“presence of AAV-specific memory T and B cells [30].”
BackgroundRescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M., & Asokan, A. (2020) · JCI Insight · doi:10.1172/jci.insight.139881 · Cited by 137
“Such NAbs arise because of natural infection or cross-reactivity between different AAV serotypes (4–7).”
Mendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
“, seropositive or seronegative) of humans has been shown to result in two distinct cellular immune responses.(44) In a recently published study, peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive and -seronegative subjects were exposed to recombinant AAV.”
BackgroundImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
“In vitro studies with human PMBCs from wild-type AAV-infected donors showed a role for interleukin-1b (IL-1b) in B cell maturation and capsid NAb production, which was confirmed in mice using a neutralizing IL-1b antibody.(43) Several studies in knockout mice have shown that TLR9 may or may not be dispensable for caps…”
BackgroundPipe, S., Leebeek, F. W. G., Ferreira, V., Sawyer, E. K., & Pasi, J. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.015 · Cited by 92
“One study suggests, however, that memory CD8 cytotoxic T cells in AAV seropositive donor peripheral-blood mononuclear cells (PBMCs) secrete tumor necrosis factor alpha (TNF-a) in response to AAV capsid peptides rather than IFN-g.(35) Therefore, by focusing on IFN-g responses, trials may be overlooking key CD8 T cell m…”
BackgroundT Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
“One study showed that peripheral blood mononuclear cells from AAV2 seronegative donors mount a robust IFN-g-secreting natural killer cell response to in vitro culture with an AAV capsid peptides while those from seropositive individuals showed activation of tumor necrosis factor-a producing CD8 T cells (36).”
BackgroundSmith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86
“moDCs have been previously identified as the main cells secreting IL-6 and IL-1b in response to AAV in human blood (43), or activation of T follicular helper T cells in the mouse model of muscle gene transfer (47, 48).”
BackgroundSelf-citationMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
“Thus, NAbs remain an impediment to more widespread use of AAV gene therapy, as well as restrict the ability to re-administer the vector, if needed [4,28].”
BackgroundResultInfluentialSelf-citationShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
“Activation of monocytederived DCs rather than pDCs may be more critical for the B cell response.(66,67) Our findings contribute to a more complete understanding of basic immunological mechanisms underlying deleterious immune responses to AAV gene therapy and provide insight toward the development of targeted immune su…”
BackgroundLong, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.008 · Cited by 76
“Additionally, other studies have demonstrated that TNF-a appears to be the primary cytokine secreted by CD8 T cells in response to the AAV capsid, and these cells could readily be detected in AAV2 seropositive individuals.(38)”
ResultSelf-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“In three of the four patients, circulating T-cells that produced TNFa upon stimulation with NAGLU peptides were detected but later subsided, indicative of the development of tolerance (173).”
BackgroundInfluentialEngineered extracellular vesicles as brain therapeutics
Lino, M. M., Simões, S., Tomatis, F., Albino, I., Barrera, A., Vivien, D., Sobrino, T., & Ferreira, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.037 · Cited by 68
Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity
You, Y., Tian, Y. P., Guo, R., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Hsu, W., Liu, Y., Hu, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae883 · Cited by 71
Gross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 66
“Importantly, the inhibition of IL-1b through monoclonal antibodies resulted in decreased anti-AAV antibody formation both in vitro, in human PBMCs and in vivo in C57Bl6 mice challenged with an AAV8 vector (97).”
BackgroundSelf-citationDelivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“Here, treatment of peripheral blood mononuclear cells (PBMCs) from seropositive patients with AAV capsids was associated with induction of an effector memory CD8+ phenotype (detected via granzyme B and CD107a degranulation marker expression), whilst PBMCs from seronegative patients treated with AAV was correlated with…”
Discussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 54
Progress and challenges of gene therapy for Pompe disease
Ronzitti, G., Collaud, F., Laforet, P., & Mingozzi, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.67 · Cited by 51
“Ongoing work aimed at the identification of immunosuppressive treatments that would allow for vector re-administration yielded promising preclinical results (123-125), and some of them has been translated to the clinic (NCT02240407, University of Florida).”
BackgroundSelf-citationSamelson-Jones, B. J., Finn, J. D., Favaro, P., Wright, J. F., & Arruda, V. R. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.001 · Cited by 50
“IL-1b has recently been implicated in the innate immune response to AAV.(36) Th17 cells have been implicated in the initial development of anti-FVIII inhibitors in HA patients(37) and after hFVIII exposure in HA mice.”
BackgroundInnate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“37 We found that IL-1 blockade prevented CD8 + T cell responses to the transgene product in hepatic gene transfer but had little effect on antibody formation against either transgene product or capsid.”
InfluentialGernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“The fact that it was not predicted in animal models can be due to the pre-existing immunity to AAV capsid in humans.(30,52,53) Even if monkeys are natural hosts of AAV, their pre-existing capsid-specific T cells differ from those of humans, with an effector phenotype compared to a memory phenotype in humans, and also…”
BackgroundDevelopment challenges associated with rAAV-based gene therapies
Bolt, M. W., Brady, J. T., Whiteley, L. O., & Khan, K. N. M. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.57 · Cited by 49
Exploiting Single-Cell Tools in Gene and Cell Therapy
Bode, D., Cull, A. H., Rubio-Lara, J. A., & Kent, D. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702636 · Cited by 46
Fader, K. A., Pardo, I. D. R., Kovi, R. C., Somps, C. J., Wang, H. H., Vaidya, V. S., Ramaiah, S. K., & Sirivelu, M. P. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.017 · Cited by 41
“AAV-mediated immunogenicity typically involves T-cell and humoral responses to the vector capsid or transgene product, which may lead to death of the transduced cells and loss of therapeutic efficacy (Ertl and High, 2017; Kuranda et al., 2018; Ronzitti et al., 2020).”
BackgroundUnderstanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
“13,110 Preclinical data and natural AAV infections in human population Importantly, most of the AAV immunological studies performed in mice have shown that, upon AAV administration, mouse CD8 + T cells do not proliferate in vivo when re-exposed to AAV-derived antigens (capsid or trans-gene).”
Self-citationComplement System Response to Adeno-Associated Virus Vector Gene Therapy
Kropf, E., Markusic, D. M., Majowicz, A., Mingozzi, F., & Kuranda, K. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.194 · Cited by 39
Self-citationUncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Yang, F., Patton, K., Kasprzyk, T., Long, B. R., Gupta, S., Zoog, S. J., Tracy, K., & Vettermann, C. (2021) · Gene Therapy · doi:10.1038/s41434-020-00214-w · Cited by 43
Patton, K. S., Harrison, M. T., Long, B. R., Lau, K., Holcomb, J., Owen, R. E., Kasprzyk, T., Janetzki, S., Zoog, S. J., & Vettermann, C. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.012 · Cited by 43
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
AAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Self-citationCosta-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
“…events has centred on adaptive immune responses triggered by the vector capsid 2,17 , the role of capsid and genome sensing by toll-like receptors (TLRs) on peripheral innate immune cells in the induction of adaptive immunity 18 – 22 , as well as on humoral and complement responses 23 – 25 .”
Self-citationThe immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
“57,58 Further basic research should aim to identify other targetable innate and cytokine signaling pathways that may be derived from the vector (pathogen-associated molecular patterns) or tissue damage (damage-associated molecular patterns) and promote B and/or T cell responses.”
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 32
Basic Principles and Clinical Applications of CRISPR-Based Genome Editing
Lim, J. M., & Kim, S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.2.105 · Cited by 28
Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes
Ferriero, R., Bruno, G., Padula, A., Pisano, S., Boffa, I., Gargaro, M., Imperatore, T., Battipaglia, M., Vivenzio, S., Perna, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57382-9 · Cited by 26
“Toll-like receptor engagement by AAV components in macrophages, DCs, and liver ECs leads to the generation of anti-AAV cytotoxic CD8 + T cells and antibodies 42 – 46 .”
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Military Medical Research · doi:10.1186/s40779-023-00486-4 · Cited by 27
Wang, L., Warzecha, C. C., Kistner, A., Chichester, J. A., Bell, P. L., Buza, E. L., He, Z., Pampena, M. B., Couthouis, J., Sethi, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.007 · Cited by 26
“Indeed, the production of type I interferons (IFNs) has been shown to play a role in the amplification of adaptive anti-AAV responses.(9,11,12) Although AAV vector systems confer reduced immunological response as compared with other vector systems, immune suppression may provide benefit in maximizing transduction effi…”
BackgroundVandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
“cellular immune responses, a recent study highlighted two new distinct profiles (56).”
BackgroundXie, B., Wang, X., Pan, Y., Jiang, G., Feng, J., & Lin, Y. (2020) · Theranostics · doi:10.7150/thno.46992 · Cited by 25
“Clinical trials have indicated that AAV triggers an immune response mediated by capsid-specific T cells, including both CD8+ and CD4+ T cells [49-51].”
BackgroundRathbone, T., Ates, I., Fernando, L. P., Addlestone, E., Lee, C. M., Richards, V. P., & Cottle, R. N. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0134 · Cited by 24
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
Gehrke, M., Diedrichs‐Möhring, M., Bogedein, J., Büning, H., Michalakis, S., & Wildner, G. (2022) · Cells · doi:10.3390/cells11121881 · Cited by 20
“The CD11c+/CD14+ monocyte-derived DCs (moDCs) responded to LPS with IL-1β, but not IFN-β, while an increased subpopulation of moDC was detected that coproduced both cytokines in response to all three AAV vectors and to LPS. MoDCs are important players in viral infections and are very efficient in priming of cytotoxic…”
BackgroundInfluentialHelfer-Hungerbuehler, A. K., Shah, J., Meili, T., Boenzli, E., Li, P., & Hofmann‐Lehmann, R. (2021) · Viruses · doi:10.3390/v13081636 · Cited by 21
“Adeno-associated virus (AAV)-based vectors represent promising candidates for therapeutic gene transfer, due to their lack of involvement in human diseases and their display of low immunogenicity [15].”
BackgroundLam, B. W. S., Tan, M., Gao, C. J., Pham, T. T., Tran, L. T. N., Nguyen, L. N., Sidik, H., Lim, M. B. H., Le, A. H., Nguyen, T. T. T., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70116 · Cited by 23
The intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Notarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 21
“57,58 It is important to note that capsid ‐ specific CD8+ T cell responses are primarily triggered by a limited set of AAV peptide epitopes, with only 145 peptides being immunodominant.”
BackgroundNo light without the dark: Perspectives and hindrances for translation of cardiac optogenetics
Richter, C., & Bruegmann, T. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.08.013 · Cited by 20
Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy
Lee, S., Lee, Y. J., Kong, J., Ryu, H. W., Shim, Y., Han, J. Y., Woo, H., Kim, S. Y., Cho, A., Lim, B. C., et al. (2022) · Brain and Development · doi:10.1016/j.braindev.2021.12.006 · Cited by 20
In vivo base editing rescues primary hyperoxaluria type 1 in rats
Chen, Z., Zhang, D., Zheng, R., Yang, L., Huo, Y., Zhang, D., Fang, X., Li, Y., Xu, G., Li, D., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.11.029 · Cited by 19
The HLA class-II immunopeptidomes of AAV capsids proteins
Brito-Sierra, C. A., Lannan, M. B., Siegel, R. W., & Malherbe, L. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067399 · Cited by 17
Xicluna, R., Schwalie, P. C., Bell, E., von Tell, D., Steiner, G., Seeger, E., Heeren, J. J. F., Turksma, A. W., Pouw, R. B., Schwandt, T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101551 · Cited by 16
“19 In our blood donor cohort, IL-6 release was significantly up-regulated upon AAV2 treatment, while only few donor samples showed IL-6 release upon AAV8 treatment.”
Choi, S. J., Yi, J. S., Lim, J., Tedder, T. F., Koeberl, D. D., Jeck, W. R., Desai, A. K., Rosenberg, A. S., Sun, B., & Kishnani, P. S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3509 · Cited by 14
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
“T-cell responses directed to AAV capsids have also been demonstrated, hypothetically leading to destruction of transduced host cells and a decline in transgene expression [4, 31, 34 – 37].”
Dong, X., Dong, X., Gao, F., Liu, N., Liang, T., Zhang, F., Fu, X., Pu, L., & Chen, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16300 · Cited by 13
Li, P., Boenzli, E., Hofmann‐Lehmann, R., & Helfer-Hungerbuehler, A. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212811 · Cited by 14
Xicluna, R., Avenel, A., Vandamme, C., Devaux, M., Jaulin, N., Couzinié, C., Duff, J. L., Charrier, A., Guilbaud, M., Adjali, O., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.225 · Cited by 14
“30 Finally, another major concern in AAV-mediated gene transfer is the fact that IFN c secretion alone, as measured today, is not suf fi cient to predict the immune outcome of gene transfer.”
Simmons, E. M., Wen, Y., Li, J., Qian, Y., Wong, L. C., Konrad, R. J., & Bivi, N. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113397 · Cited by 11
Potter, H., Boyd, T. D., Clarke, P., Pelak, V. S., & Tyler, K. L. (2020) · F1000Research · doi:10.12688/f1000research.23729.1 · Cited by 11
Jarvi, N. L., Hofman, K., Venkatesh, A., Gorecki, E., & Balu‐Iyer, S. V. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.006 · Cited by 10
Goyal, A., Gardner, M. R., Mayer, B. T., Jerome, K. R., Farzan, M., Schiffer, J. T., & Ojeda, E. F. C. (2022) · Science Advances · doi:10.1126/sciadv.abj5666 · Cited by 10
Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products
Mann, C. J., Giblin, J., Braun, M., Schmid, F., Sørensen, M. R., Caferra, P., Hudák, A., Letoha, T., Coderch, N., Hickling, T. P., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102422 · Cited by 7
“8,55 Capsid-specific T cells normally display high cross-reactivity 8,84,85 and show a memory phenotype 84,86,87 but are not frequently detected in the peripheral blood.”
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
“35 In Figure 2.”
InfluentialAAV Immunogenicity: New Answers Create New Questions
Shirley, J. L., & Herzog, R. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.004 · Cited by 7
“Klaudia Kuranda et al.(1) find evidence that capsid-derived peptides may stimulate the response.”
BackgroundGlenn, J. D., Negash, H., Henry, W., Qian, R., Liu, Y., Danos, O., Bruder, J. T., & Karumuthil-Melethil, S. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104823 · Cited by 6
Warrington, S., Hoang, T. T., Seirup, M., Abdelhamid, L., Saha, H., Bing, S. J., Saleh, S., Phue, J., & Mazor, R. (2025) · Gene Therapy · doi:10.1038/s41434-025-00528-7 · Cited by 7
“Further studies are needed to identify the immunological basis for this sex-based differences and potentially develop mitigation strategies and to investigate the clinical signi fi cance of these sex differences.”
Abdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 7
“Kuranda et al. observed limited CD4 + T cell activation by AAV2 capsid peptides, with increased IL-2 and modest IFN-γ secretion in vitro (49).”
Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities
Belova, L., Лавров, А. В., & Smirnikhina, S. (2022) · BioEssays · doi:10.1002/bies.202200055 · Cited by 6
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1
Ates, I., Stuart, C., Rathbone, T., Barzi, M., He, G., Major, A. M., Shankar, V., Lyman, R. A., Angner, S. S., Mackay, T. F. C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000424 · Cited by 6
“Anti-capsid neutralizing antibodies also contribute to pre-existing immunity and inhibit AAV transduction in animal models (12-15) and humans (16-19).”
Optogenetic Control of Muscles: Potential Uses and Limitations
Cohen, E. M., Knapman, F. L., & Bilston, L. E. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.236 · Cited by 5
“61 In the context of optogenetic control of muscles, the immunogenicity of the AAV capsid can interfere with successful transduction, and the opsin itself can be targeted by the immune system, resulting in anti-ChR2 antibody formation.”
Ramella Gal, I., Arez, F., Correia, I. P., Domenici, G., Fernandes, S., Silva, G., Saldanha, I., Duarte, N., Freitas, C., Alves, P. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-31044-8 · Cited by 4
“Differences between the PBMC and/or PHH donors employed (i.e., previous AAV exposure and infection status at the time of collection) could have an impact on both kinetics and magnitude of rAAV-driven innate immune responses, explaining the observed variability among the different cultures.”
InfluentialTomczyk, M., Kraszewska, I., Mąka, R., Waligórska, A., Dulak, J., & Jaźwa, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240691 · Cited by 5
“The study also demonstrated that in subjects previously exposed to WT AAV both IL-1β and IL-6 cytokines triggered the differentiation of capsid-specific memory B cells into antibody-secreting cells and anti-capsid antibody production [42].”
BackgroundResultInfluentialImmunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 6
“Tumor necrosis factor-α was also increased but this increase was observed in seropositive individuals, suggesting a different NK response in naïve versus donors previously infected with AAVs [25].”
InfluentialAlissa, M., Aldurayhim, M., Abdulaziz, O., Alsalmi, O., Awad, A., Algopishi, U. B., Alharbi, S., Safhi, A. Y., Khan, K. H., & Uffar, C. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102857 · Cited by 3
Re-administration of AAV-mediated gene therapy for OTOF-related deafness: a single-arm trial
Fan, X., Zhang, L., Gao, Z., Han, L., Yang, P., Wang, D., Yu, H., Cao, Q., Jiang, L., Chen, X., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04505-4 · Cited by 2
“Cyto-toxic T lymphocyte-mediated elimination of transduced cells has been reported in other contexts, sometimes leading to efficacy decline or AEs 32,33 .”
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 3
Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination
Naumova, D. A., Krokunova, T., Maksimov, D. O., Mityaeva, O. N., Astakhova, E. A., & Volchkov, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020816 · Cited by 3
Xicluna, R., Yamada, K., Gonzalez-Visiedo, M., Greenwood, C. M., Zaugg, D., Waiz, D., Steiner, G., Hahn, K., Schwandt, T., Otteneder, M. B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.014 · Cited by 2
Gene Therapy and Cell Therapy: Bioanalytical Challenges and Practical Solutions
Jani, D., Boyanapalli, R., & Cao, L. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-97193-9_5 · Cited by 1
Ravichandran, A. J., Mazurek, R., & Ishikawa, K. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_22 · Cited by 1
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Self-citationAssaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Balasubramanian, A., Prachař, M., Klaproth, B., Copeland, V., Justesen, S. F. L., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641289 · Cited by 2
Kozikowski, A., Wang, Q., Yang, C., Gordon, N., Ciociola, K. M., Yapa, A. S., Villa, C., Lambotte, P., Pisani, T., Esfandiari, J., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00559-0
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Metadata
- Authors
- Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F.
- Affiliations
- Inserm (FR)
- Genethon (France) (FR)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-10-22
- Volume
- 128
- Issue
- 12
- Pages
- 5267-5279
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6264647
- OpenAlex
- W2897401411
- Cited by
- 104
- References
- 79
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 18 · 2021: 16 · 2020: 17 · 2019: 11 · 2018: 1
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- E-Rare
- European Commission (667751, FP7-PEOPLE-2012-CIG, 333628, 617432)
- Institut National de la Santé et de la Recherche Médicale
- Centre International de Mathématiques et Informatique de Toulouse
- FP7 People: Marie-Curie Actions (FP7-PEOPLE-2012-CIG)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, memory CD8+ T cells, natural killer cells, monocyte-derived dendritic cells, IL-1β, interleukin-6, TNF-α, humoral immune response, vector immunogenicity, gene therapy
- MeSH terms
- Dependovirus, Adolescent, Adult, Aged, Aged, 80 and over, Capsid, Cell Line, Dendritic Cells, Female, Genetic Vectors, Humans, Immunologic Memory, Lymphocytes, Male, Middle Aged, Genetic Therapy, Interleukin-6, Gene Transfer Techniques, Interleukin-1beta, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.